Skip to main content
. 2022 May 27;81:104083. doi: 10.1016/j.ebiom.2022.104083

Table 3.

Dose-response relationship between the DNAm scores and breast cancer risk in subset I, II, and III.

Predictors Quartiles Person-years Cases HR (95% CI)a P-trend
AgeAccelPheno
Q1 5987·4 27 1·00 (Ref·) 0·759
Q2 5185·7 15 0·83 (0·17-3·98)
Q3 4980·9 18 0·79 (0·22-2·81)
Q4 4398·6 15 0·48 (0·22-1·04)

AgeAccelGrim
Q1 8168·7 35 1·00 (Ref·) 0·320
Q2 6061·8 18 0·36 (0·10-1·33)
Q3 3828·0 15 0·58 (0·27-1·25)
Q4 2494·1 7 0·12 (0·03-0·47)

MRscore-8CpGs Q1 7058·5 28 1·00 (Ref·) 0·006
Q2 5820·7 25 0·80 (0·19-3·34)
Q3 4645·3 15 0·55 (0·15-1·92)
Q4 3028·1 7 0·16 (0·04-0·74)

Abbreviations: DNAm, DNA methylation; HR, hazard ratio; CI, confidence interval; AgeAccelPheno, DNA methylation phenotypic age acceleration; AgeAccelGrim, DNA methylation GrimAge acceleration; MRscore-8CpGs, revised version of continuous mortality risk score with 8 CpGs.

a

Models adjusted for age, leukocyte composition, batch, educational level, smoking status (never smoker, former smoker, current smoker), alcohol consumption (grams per day), body mass index (kg/m2), diabetes, menopausal status, and postmenopausal hormone use.